Abstract
Excitotoxicity is a key molecular mechanism of perinatal brain damage and is associated with cerebral palsy and long term cognitive deficits. VIP induces a potent neuroprotection against perinatal excitotoxic white matter damage. VIP does not prevent the initial appearance of white matter lesion but promotes a secondary repair with axonal regrowth. This plasticity mechanism involves an atypical VPAC2 receptor and BDNF production. Stable VIP agonists mimic VIP effects when given systemically and exhibit a large therapeutic window. Unraveling cellular and molecular targets of VIP effects against perinatal white matter lesions could provide a more general rationale to understand the neuroprotection of the developing white matter against excitotoxic insults.
Keywords: Neuroprotection, cerebral palsy, plasticity, preterm infant, VPAC receptor, NAP, excitotoxicity, perinatal, multifactorial, ionotropic, phosphoinositide, cytoarchitectonic, astrocytic, murine, dysgeneses, isoleucine, forskolin, calmodulin, heterodimers, endopeptidases, methionine
Current Pharmaceutical Design
Title: VIP-induced Neuroprotection of the Developing Brain
Volume: 17 Issue: 10
Author(s): Sandrine Passemard, Paulina Sokolowska, Leslie Schwendimann and Pierre Gressens
Affiliation:
Keywords: Neuroprotection, cerebral palsy, plasticity, preterm infant, VPAC receptor, NAP, excitotoxicity, perinatal, multifactorial, ionotropic, phosphoinositide, cytoarchitectonic, astrocytic, murine, dysgeneses, isoleucine, forskolin, calmodulin, heterodimers, endopeptidases, methionine
Abstract: Excitotoxicity is a key molecular mechanism of perinatal brain damage and is associated with cerebral palsy and long term cognitive deficits. VIP induces a potent neuroprotection against perinatal excitotoxic white matter damage. VIP does not prevent the initial appearance of white matter lesion but promotes a secondary repair with axonal regrowth. This plasticity mechanism involves an atypical VPAC2 receptor and BDNF production. Stable VIP agonists mimic VIP effects when given systemically and exhibit a large therapeutic window. Unraveling cellular and molecular targets of VIP effects against perinatal white matter lesions could provide a more general rationale to understand the neuroprotection of the developing white matter against excitotoxic insults.
Export Options
About this article
Cite this article as:
Passemard Sandrine, Sokolowska Paulina, Schwendimann Leslie and Gressens Pierre, VIP-induced Neuroprotection of the Developing Brain, Current Pharmaceutical Design 2011; 17 (10) . https://dx.doi.org/10.2174/138161211795589409
DOI https://dx.doi.org/10.2174/138161211795589409 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biological Relevance of Lysophospholipids and Green Solutions for Their Synthesis
Current Organic Chemistry Electroacupuncture Reduces Hemiplegia Following Acute Middle Cerebral Artery Infarction with Alteration of Serum NSE, S-100B and Endothelin
Current Neurovascular Research Diffusion Tensor MRI Assessment of Skeletal Muscle Architecture
Current Medical Imaging Remyelination in Multiple Sclerosis: The Therapeutic Potential of Neural and Mesenchymal Stem/Progenitor Cells
Current Signal Transduction Therapy Editorial:Brain Hemorrhages and Future Management
Current Drug Targets Isosteviol Protects H9c2 Cells Against Hypoxia-reoxygenation by Activating ERK1/2
Cardiovascular & Hematological Disorders-Drug Targets Autophagy as a Potential Therapeutic Target in Breast Cancer Treatment
Current Cancer Drug Targets Immune Functions of Glia and Neurons in the Central Nervous System
Current Immunology Reviews (Discontinued) Transgenic Mouse Models of Tauopathy in Drug Discovery
CNS & Neurological Disorders - Drug Targets The Delivery of Personalised, Precision Medicines <i>via</i> Synthetic Proteins
Drug Delivery Letters Application of the Phage Display Technology for the Development of Peptide- mediated Drug Delivery Systems through the Blood-Brain Barrier
Current Pharmaceutical Biotechnology Herpetic (Non-Cytomegalovirus) Retinal Infections in Patients with the Acquired Immunodeficiency Syndrome
Current HIV Research Inflammatory and Vascular Alterations in Sepsis: The Role of Nitric Oxide- Dependent Mechanisms
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cross Talk Among Leukocytes, Platelets, and Endothelial Cells and its Relevance to Atherosclerosis and Coronary Heart Disease
Current Nutrition & Food Science Involvement of Toll-like Receptors in Ischemia-induced Neuronal Damage
Central Nervous System Agents in Medicinal Chemistry Melatonin Role in Experimental Arthritis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Cell Death Mechanisms in Stroke and Novel Molecular and Cellular Treatment Options
Current Neuropharmacology Biologics: An Update and Challenge of Their Pharmacokinetics
Current Drug Metabolism The Future of Neuroregenerative Therapy for Parkinson’s Disease
Current Tissue Engineering (Discontinued) Pteridine Derivatives as Modulators of Oxidative Stress
Current Drug Metabolism